Compare Biogen Inc (BIIB) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Warner Music Group Corp — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Warner Music Group Corp trades at $25.06 (market cap $13.12B). The key difference: Biogen Inc is far larger — about 2.3× Warner Music Group Corp's market cap, and Warner Music Group Corp pays a 3.19% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | WMG | |
|---|---|---|
Market Cap | $30.13B | $13.12B |
Sector | Health | Media |
52-Week High | $216.63 | $34.72 |
52-Week Low | $128.93 | $23.65 |
Enterprise Value | $37.20B | $17.42B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
Warner Music Group (WMG) trades at $24.78, down 6.17% in the past 24 hours, with a bearish technical signal and support near $23. Recent earnings show mixed results, with Q1 and Q2 2026 beats but Q3 and Q4 2025 misses. Revenue grew to $6.71B in 2025, though net income margin declined to 5.44%. Analyst consensus is bullish with 16 buy ratings, citing streaming growth and strategic renewals like the NetEase Cloud Music partnership announced July 16, 2026.
The outlook is cautiously optimistic, with strong analyst support and projected revenue growth to $7.3B in 2026. Risks include execution challenges amid leadership changes, competitive pressures, and market volatility. The current valuation at a P/E of 20.06 may appeal to growth-oriented investors, but near-term price weakness reflects earnings uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
